<?xml version="1.0" encoding="UTF-8"?>

<article article-type="research-article" dtd-version="3.0" xml:lang="eng">
   <front>
      <journal-meta>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="publisher-id">jprivateequity</journal-id>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">j50016652</journal-id>
         <journal-title-group>
            <journal-title>The Journal of Private Equity</journal-title>
         </journal-title-group>


         <publisher>
            <publisher-name>Institutional Investor LLC</publisher-name>
         </publisher>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="ppub">10965572</issn>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="epub">21688508</issn>
         <custom-meta-group xmlns:xlink="http://www.w3.org/1999/xlink"/>
      </journal-meta>
      <article-meta xmlns:xlink="http://www.w3.org/1999/xlink">
         <article-id pub-id-type="jstor">26408065</article-id>
         <title-group>
            <article-title>Pharmacoeconomics</article-title>
            <subtitle>Growth in Cancer Diagnostics Means Market Opportunity</subtitle>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author">
               <string-name>
                  <surname>Crowe</surname>
                  <given-names>Paul</given-names>
               </string-name>
               <bio>
                  <p>Paul Crowe is CEO at NuView Life Sciences in Tampa, FL. mradmin@jotopr.com</p>
               </bio>
            </contrib>
         </contrib-group>
         <pub-date pub-type="ppub">
            <day>1</day>
            <month>1</month>
            <year>2017</year>
            <string-date>WINTER 2017</string-date>
         </pub-date>
         <volume>21</volume>
         <issue>1</issue>
         <issue-id>e26408056</issue-id>
         <fpage>48</fpage>
         <lpage>50</lpage>
         <permissions>
            <copyright-statement>Copyright Â© 2017 by Institutional Investor LLC</copyright-statement>
         </permissions>
         <self-uri xlink:href="https://www.jstor.org/stable/26408065"/>
         <abstract xml:lang="eng">
            <p>Testing for precision diagnostics in cancer is underway in Food and Drug Administration clinical trials. This new technology will outdate current, inaccurate technologies (i.e., mammograms and prostate-specific antigen tests) and become part of routine health screenings. Cost savings translate to bigger profit potential for hospitals and laboratories that conduct the tests. Trends in precision medicine will turn the diagnostics sector from its current moderate value/moderate growth status to one replicating the explosive growth of biotech.</p>
         </abstract>
         <custom-meta-group>
            <custom-meta>
               <meta-name>lang</meta-name>
               <meta-value>eng</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <back>
      <ref-list content-type="unparsed-citations">
         <title>REFERENCES</title>
         <ref id="r1">
            <mixed-citation publication-type="other">American Cancer Society. "Key Statistics for Prostate Cancer | Prostate Cancer Facts." Cancer.org, 2017. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html.</mixed-citation>
         </ref>
         <ref id="r2">
            <mixed-citation publication-type="other">American Society of Clinical Oncology. "Prostate-Specific Antigen (PSA) Testing for Prostate Cancer Screening." Cancer. Net, August 26, 2015. http://www.cancer.net/research-andadvocacy/asco-care-and-treatment-recommendations-patients/prostate-specif ic-antigen-psa-testing-prostate-cancerscreening.</mixed-citation>
         </ref>
         <ref id="r3">
            <mixed-citation publication-type="other">Burns, M. "The U.S. Market for SPECT and PET Radiopharmaceuticals." Market Research Report, Bio-Tech Systems, Inc., July 2013.</mixed-citation>
         </ref>
         <ref id="r4">
            <mixed-citation publication-type="other">Mercola, J.M. "Experts Do NOT Recommend Prostate Cancer Screening." Mercola.com, November 7, 2011. https://articles.mercola.com/sites/articles/archive/2011/11/07/conventional-prostate-cancer-treatments.aspx.</mixed-citation>
         </ref>
         <ref id="r5">
            <mixed-citation publication-type="other">Miller, T. "The Next Big Medtech Boom Area? Investing in Precision Diagnostics." Medtech Engine, December 19, 2016. https://medtechengine.com/article/investing-precision-diagnostics/.</mixed-citation>
         </ref>
         <ref id="r6">
            <mixed-citation publication-type="other">Nagavarapu, U. "Prevention and Treatment of Prostate Cancer: Technologies and Global Market." BCC Research, March 2017. https://www.bccresearch.com/market-research/pharmaceuticals/prostate-cancer-treatment-marketsphm113a. html.</mixed-citation>
         </ref>
         <ref id="r7">
            <mixed-citation publication-type="other">NuView Life Sciences. "Creating Better Patient Outcomes and Lowering Costs." August 2013a. http://nuviewinfo .com/wp-content/uploads/2013/08/NuView-Summary-August-2013.pdf.</mixed-citation>
         </ref>
         <ref id="r8">
            <mixed-citation publication-type="other">NuView Life Sciences. "New Technologies that Improve Patient Care and Lower Costs." September 2013b. http://nuviewinfo .com/wp-content/uploads/2013/09/NuView-Corporate-Overview-Sep-2013-website.pdf.</mixed-citation>
         </ref>
         <ref id="r9">
            <mixed-citation publication-type="other">U.S. Census Bureau. "Age and Sex Composition: 2010." 2010 Census Briefs, 2010. https://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf.</mixed-citation>
         </ref>
         <ref id="r10">
            <mixed-citation publication-type="other">Zinberg, J.M. "When Good Intentions Do Bad Things." Real Clear Health.com, October 24, 2016. http://www.realclearhealth.com/articles/2016/10/24/when_good_ intentions_do_bad_things__110187.html.</mixed-citation>
         </ref>
      </ref-list>
   </back>
</article>
